Relevance of non-criteria antiphospholipid antibodies titers among patients with antiphospholipid syndrome and patients with systemic lupus erythematosus

Gómez-Puerta, 2014, Diagnosis and classification of the antiphospholipid syndrome, J Autoimmun, 48, 20, 10.1016/j.jaut.2014.01.006 Ardila-Suarez, 2016, Diagnosis of antiphospholipid syndrome: From an historical perspective to the emergence of new autoantibodies, Med Clin (Barc), 146, 555, 10.1016/j.medcli.2016.01.005 Pengo, 2010, Clinical course of high-risk patients diagnosed with antiphospholipid syndrome, J Thromb Haemost, 8, 237, 10.1111/j.1538-7836.2009.03674.x Sciascia, 2012, Clinical accuracy for diagnosis of antiphospholipid syndrome in systemic lupus erythematosus: Evaluation of 23 possible combinations of antiphospholipid antibody specificities, J Thromb Haemost, 10, 2512, 10.1111/jth.12014 Saccone, 2017, Antiphospholipid antibody profile based obstetric outcomes of primary antiphospholipid syndrome: the PREGNANTS study, Am J Obstet Gynecol, 216, 525 Nakamura, 2018, First-Line Non-Criterial Antiphospholipid Antibody Testing for the Diagnosis of Antiphospholipid Syndrome in Clinical Practice: A Combination of Anti–β2-Glycoprotein I Domain I and Anti–Phosphatidylserine/Prothrombin Complex Antibodies Tests, Arthritis Care Res, 70, 627, 10.1002/acr.23310 Hoxha, 2017, Antiphosphatidylserine/prothrombin antibodies as biomarkers to identify severe primary antiphospholipid syndrome, Clin Chem Lab Med, 55, 890, 10.1515/cclm-2016-0638 Canti, 2018, Antiphosphatidylserine/prothrombin antibodies in Antiphospholipid Syndrome with intrauterine growth restriction and preeclampsia, J Rheumatol, 45, 1263, 10.3899/jrheum.170751 Sciascia, 2014, Anti-prothrombin (aPT) and anti-phosphatidylserine /prothrombin (aPS/PT) antibodies and the risk of thrombosis in the antiphospholipid syndrome. A systematic review, Thromb Haemost, 111, 354, 10.1160/TH13-06-0509 Mahler, 2016, Autoantibodies to domain 1 of beta 2 glycoprotein I determined using a novel chemiluminescence immunoassay demonstrate association with thrombosis in patients with antiphospholipid syndrome, Lupus, 25, 911, 10.1177/0961203316640366 Nojima, 2017, Detection of antibodies against domain 1 of β2-glycoprotein I is key in predicting thromboembolic complications in patients with systemic lupus erythematosus, Thromb Res, 153, 83, 10.1016/j.thromres.2017.02.001 Banzato, 2011, Antibodies to domain I of β2 glycoprotein I are in close relation to patients risk categories in antiphospholipid syndrome (APS), Thromb Res, 128, 583, 10.1016/j.thromres.2011.04.021 Pengo, 2015, Antiphospholipid syndrome: antibodies to domain 1 of β2-glycoprotein I correctly classify risk, J Thromb Haemost, 13, 782, 10.1111/jth.12865 Tan, 1982, The 1982 revised criteria for the classification of systemic lupus erythematosus, Arthritis Rheum, 25, 1271, 10.1002/art.1780251101 Miyakis, 2006, International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS), J Thromb Haemost, 4, 295, 10.1111/j.1538-7836.2006.01753.x Piette, 1993, Exclusion criteria for primary antiphospholipid syndrome, J Rheumatol, 20, 1802 Pengo, 2009, Subcommittee on lupus anticoagulant/antiphospholipid antibody of the scientific and standardisation committee of the international society on thrombosis and haemostasis. Update of the guidelines, J Thromb Haemost, 7, 1737, 10.1111/j.1538-7836.2009.03555.x Zhang, 2018, Antibodies to phosphatidylserine/prothrombin (aPS/PT) enhanced the diagnostic performance in Chinese patients with antiphospholipid syndrome, Clin Chem Lab Med, 56, 939, 10.1515/cclm-2017-0811 Mattia, 2014, IgA anticardiolipin and IgA anti-β2 glycoprotein I antibody positivity determined by fluorescence enzyme immunoassay in primary antiphospholipid syndrome, Clin Chem Lab Med, 52, 1329, 10.1515/cclm-2014-0039 Zohoury, 2017, Closing the Serological Gap in the Antiphospholipid Syndrome: The Value of “Non criteria” Antiphospholipid Antibodies, J Rheumatol, 44, 1597, 10.3899/jrheum.170044 Žigon, 2019, Added value of non-criteria antiphospholipid antibodies for antiphospholipid syndrome: Lessons learned from year-long routine measurements, Clin Rheumatol, 38, 371, 10.1007/s10067-018-4251-7 Gómez-Puerta, 2005, Long-term follow-up in 128 patients with primary antiphospholipid syndrome: Do they develop lupus?, Medicine (Baltimore), 84, 225, 10.1097/01.md.0000172074.53583.ea Cervera, 2015, Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: A multicentre prospective study of 1000 patients, Ann Rheum Dis, 74, 1011, 10.1136/annrheumdis-2013-204838 Taraborelli, 2017, Longterm Outcome of Patients with Primary Antiphospholipid Syndrome: A Retrospective Multicenter Study, J Rheumatol, 44, 1165, 10.3899/jrheum.161364 Paule, 2018, Classification of primary antiphospholipid syndrome as systemic lupus erythematosus: Analysis of a cohort of 214 patients, Autoimmun Rev, 17, 866, 10.1016/j.autrev.2018.03.011 Houben, 2016, Diagnosing ANCA-associated vasculitis in ANCA positive patients A retrospective analysis on the role of clinical symptoms and the ANCA titre, Medicine (Baltimore), 95, e5096, 10.1097/MD.0000000000005096 Tonello, 2019, IgG phosphatidylserine/prothrombin antibodies as a risk factor of thrombosis in antiphospholipid antibody carriers, Thromb Res, 177, 157, 10.1016/j.thromres.2019.03.006 Abu-Zeinah, 2019, Thrombotic risk factors in patients with antiphospholipid syndrome: A single center experience, J Thromb Thrombolysis, 48, 233, 10.1007/s11239-019-01836-7 Khawaja, 2020, Loss of antiphospholipid antibody positivity post-thrombosis in SLE, Lupus Sci Med, 7, e000423, 10.1136/lupus-2020-000423 Nuri, 2017, Long-term use of hydroxychloroquine reduces antiphospholipid antibodies levels in patients with primary antiphospholipid syndrome, Immunol Res, 65, 17, 10.1007/s12026-016-8812-z